Saurabh Dahiya, MD, FACP, on CAR-T KITE-363's Safety Profile in R/R B-Cell Lymphoma
The associate professor of medicine at Stanford University School of Medicine discussed safety and efficacy data from a study presented at EHA's 2025 congress.
This video originally appeared on our sister site, OncLive®.
"At the highest dose level in CAR naive patients, we observed an objective overall response rate of 87% and a complete remission rate of 78%."
Kite's KITE-363, a dual CD19 and CD20-directed chimeric antigen receptor (CAR) T-cell therapy, is currently being evaluated for the treatment of relapsed/refractory (r/r) B-cell lymphoma in a phase 1 clinical trial (NCT04989803). Data from this trial were presented at the European Hematology Association (EHA) 2025 Congress, held June 12 to 15, both virtually and in Milan, Italy.
During the conference, CGTLive®'s sister site, OncLive®, interviewed Saurabh Dahiya, MD, FACP, an associate professor of medicine at Stanford University School of Medicine and the clinical director of cancer cell therapy in the Division of Blood and Marrow Transplantation and Cell Therapy at Stanford Medicine, about the findings. Dahiya went over the safety profile of the CAR-T in the trial and also touched on the efficacy results.
Newsletter
Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.
